Updated guidance issued jointly by the American Academy of Neurology and the American Headache Society recommends that newer migraine therapies targeting calcitonin gene-related peptide should be considered first-line preventive treatments. The recommendations, representing the first major update since 2012, aim to help clinicians identify which preventive medications are most effective for patients experiencing episodic and chronic migraines according to author Rebecca Burch of the University of Vermont Larner College of Medicine in Burlington, as reported by Medpagetoday and STAT.
New Guidelines Recommend CGRP-Targeting Drugs for Migraine Prevention
CGRP is a potent vasodilator and protein that normally helps control blood pressure by expanding blood vessels, but excess levels are thought to activate nerves in the brain and cause inflammation by binding to receptors on the trigeminal nerve, according to Medpagetoday, drugs.com, and migraineagain.com. The guidelines state that preventive treatments should be offered to people experiencing four or more migraine days per month, four or more moderate-to-severe headache days per month, or whenever migraines interfere with an individual’s ability to work or complete daily tasks, noted Burch in coverage by Medpagetoday and STAT.
Evolution of Migraine Therapeutics Since 2012
The updated recommendations reflect a wealth of new treatments introduced since the previous 2012 guidance, led by the CGRP-targeted therapy category. In 2018, erenumab (Aimovig) became the first monoclonal antibody approved for migraine prevention, followed soon after by fremanezumab (Ajovy), galcanezumab (Emgality), and eptinezumab (Vyepti). Additionally, oral CGRP receptor antagonists—known as gepants—including rimegepant (Nurtec) and atogepant (Qulipta), were approved for prevention in 2021, as detailed by Medpagetoday.
Prior to the introduction of CGRP-targeted therapies, first-line preventives were limited to medications developed for other conditions that coincidentally showed some efficacy, such as beta-blockers, calcium channel blockers for hypertension, tricyclic antidepressants, and antiseizure agents like topiramate and valproate, alongside onabotulinumtoxinA (Botox) for chronic migraine. According to migraineagain.com, preapproval clinical studies, post-market observation, and extensive clinical experience confirmed that the efficacy and tolerability of CGRP-targeting therapies equal or exceed previous first-line treatments, with serious adverse events remaining rare.
Clinical Evidence and Potential Additional Health Benefits
The systematic review underpinning the guidelines evaluated 217 studies. High-confidence evidence indicated that patients with chronic migraine experienced fewer headaches with fremanezumab, galcanezumab, and onabotulinumtoxinA, while moderate-confidence evidence supported benefits from atogepant, eptinezumab, erenumab, topiramate, and valproate, per Medpagetoday. Furthermore, a separate recent study published in Neurology found that patients taking CGRP inhibitors had a lower risk of developing glaucoma compared to those taking other migraine medications.
Insurance Hurdles and Access Challenges
Despite expanded eligibility—with an estimated 15% of Americans experiencing migraines, disproportionately affecting women—many patients remain unaware they qualify or face administrative barriers. Joanna Kempner, a sociology professor at Rutgers University noted in STAT that strong recommendations provide physicians with necessary backing in fights for prior authorization. However, migraineagain.com notes that step therapy processes and insurance delays continue to cause obstacles, disproportionately impacting patients with reduced resources and increasing the risk of refractory migraine.
